Vericiguat
Brand names: Verquvo · Active ingredient: Vericiguat
In short: VERQUVO® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% .
What is Vericiguat used for?
VERQUVO® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% .
⚠ Boxed warning (FDA's strongest warning)
Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm [see Dosage and Administration (2.2), Warnings and Precautions (5.1), and Use in Specific Populations (8.3)].
Vericiguat dosage
The recommended starting dose of VERQUVO is 5 mg orally once daily with food.
For patients at risk of symptomatic hypotension, the recommended starting dose is 2.5 mg orally once daily with food .
Double the dose approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.
For patients who are unable to swallow whole tablets, VERQUVO may be crushed and mixed with water immediately before administration .
Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with VERQUVO .
How to take Vericiguat — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Dosing Instructions
If a dose is missed, it should be taken as soon as the patient remembers on the same day of the missed dose. Patients should not take two doses of VERQUVO on the same day.
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for one month after the final dose [see Contraindications (4), Warnings and Precautions (5.1) and Use in Specific Populations (8.1, 8.3)].
Pregnancy
Advise women who are exposed to VERQUVO during pregnancy to report their pregnancy to their healthcare provider. Health care providers should report any prenatal exposure to VERQUVO by calling 1-877-888-4231 or at https://pregnancyreporting.verquvo-us.com. .
Lactation
Advise women not to breastfeed during treatment with VERQUVO .
Warnings & precautions
Do not take this medicine if: VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators .
VERQUVO is contraindicated in pregnancy .
Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose .
Vericiguat side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
VERQUVO was evaluated in VICTORIA, which included 2,519 patients treated with VERQUVO (up to 10 mg once daily). The mean duration of VERQUVO exposure was 1 year, and the maximum duration was 2.6 years . Table 1 lists adverse drug reactions occurring more commonly with VERQUVO than placebo and in ≥5% of patients treated with VERQUVO in VICTORIA.
Adverse Drug Reaction | VERQUVO % N = 2,519 | Placebo % N = 2,515
Hypotension | 16 | 15
Anemia | 10 | 7
VELOCITY
The safety and tolerability of VERQUVO 5 mg once daily as a starting dose was evaluated in VELOCITY, a single-arm, open-label, 2-week study in 106 patients with symptomatic chronic heart failure (NYHA class II–IV) and left ventricular ejection fraction < 45%. Patients were excluded from the study if they experienced symptomatic hypotension within 4 weeks before screening. Treatment initiation with VERQUVO 5 mg once daily in VELOCITY was similarly tolerated as treatment initiation of 2.5 mg once daily in the VICTORIA study.
Drug interactions
VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators .
Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended because of the potential for hypotension .
About this medicine
VERQUVO tablets contains vericiguat, a soluble guanylate cyclase stimulator.
The chemical name of vericiguat is methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b] pyridin-3-yl] pyrimidin-5-yl} carbamate. The molecular formula is C19H16F2N8O2 and the molecular weight is 426.39 g/mol.
The chemical structure is:
Vericiguat is a white to yellowish powder that is freely soluble in dimethyl sulfoxide; slightly soluble in acetone; very slightly soluble in ethanol, acetonitrile, methanol, and ethyl acetate; and practically insoluble in 2-propanol.
VERQUVO® is available as film-coated tablets for oral administration, containing 2.5 mg of vericiguat, 5 mg of vericiguat or 10 mg of vericiguat.The tablet inactive ingredients are croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.
The film coating contains hypromellose, talc and titanium dioxide. The film coating for the 5 mg of VERQUVO tablet also contains ferric oxide red. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d. Read the full official label on DailyMed.
Related medicines
Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol